109 related articles for article (PubMed ID: 22571214)
1. Regional variation in Medicare Part D drug spending.
Mukherjee D; Mukherjee C
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571214
[No Abstract] [Full Text] [Related]
2. Regional variation in Medicare Part D drug spending.
Flansbaum B
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571215
[No Abstract] [Full Text] [Related]
3. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
4. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
5. Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.
Socal MP; Wang Y; Plummer E; Anderson GF; Bai G
JAMA; 2024 Jan; 331(1):72-75. PubMed ID: 38095888
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for Lowering Prescription Drug Spending in Public Programs.
Jazowski SA; Dusetzina SB
Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
[No Abstract] [Full Text] [Related]
7. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
Dusetzina SB; Huskamp HA; Keating NL
JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
[TBL] [Abstract][Full Text] [Related]
8. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
[TBL] [Abstract][Full Text] [Related]
9. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
Dusetzina SB; Bach PB
JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
[No Abstract] [Full Text] [Related]
10. Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019.
Duvalyan A; Pandey A; Vaduganathan M; Essien UR; Halm EA; Fonarow GC; Sumarsono A
J Am Heart Assoc; 2021 Dec; 10(24):e022644. PubMed ID: 34889109
[No Abstract] [Full Text] [Related]
11. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
12. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
Dusetzina SB; Conti RM; Yu NL; Bach PB
JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
[TBL] [Abstract][Full Text] [Related]
13. Relief in Sight - Estimated Savings under Medicare Part D Redesign.
Dusetzina SB
N Engl J Med; 2021 Dec; 385(26):e93. PubMed ID: 34758246
[No Abstract] [Full Text] [Related]
14. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
Frank RG
Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
[No Abstract] [Full Text] [Related]
15. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
16. Demand for prescription drugs under non-linear pricing in Medicare Part D.
Jung K; Feldman R; McBean AM
Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
[TBL] [Abstract][Full Text] [Related]
17. Determinants of U.S. Prescription Drug Utilization using County Level Data.
Nianogo T; Okunade A; Fofana D; Chen W
Health Econ; 2016 May; 25(5):606-19. PubMed ID: 25903420
[TBL] [Abstract][Full Text] [Related]
18. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.
Egilman AC; Zhang AD; Wallach JD; Ross JS
Ann Intern Med; 2019 Oct; 171(7):521-523. PubMed ID: 31404926
[No Abstract] [Full Text] [Related]
19. Medicare Part D update--lessons learned and unfinished business.
Neuman P; Cubanski J
N Engl J Med; 2009 Jul; 361(4):406-14. PubMed ID: 19625722
[No Abstract] [Full Text] [Related]
20. Medication Access in America and Medicare Part D: Prescription Shopping Saves but May Be Costly.
Upchurch G; Disco ME; Visco JL; Huffman KF
J Am Geriatr Soc; 2018 Jan; 66(1):33-40. PubMed ID: 29124745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
